A. Mottok, Ulm (Germany), et al.
Authors Conclusion from the abstract: Here we identified candidate driver genes with clear evidence of somatic mutations in PMBCL, the majority being distinct from DLBCL. We observed an enrichment of somatic mutations affecting genes involved in the JAK‐STAT‐ and NFkB‐pathway, and propose that the IRF‐pathway is critically involved in PMBCL pathogenesis.
A. Hayden, Vancouver, B.C. (Canada), et al.
Authors Conclusion from the abstract: Overall outcomes of PMBCL pts primarily treated with R‐CHOP are favourable with a 5 y OS of 89%. Changing to a PET‐adapted approached has reduced the use of CRT by over 60% without compromising cure rates. EOT PETneg scan is associated with excellent outcomes with 90% cure rate using modern D criteria. In contrast, D5 have a very poor outcome and may benefit from alternate treatment approaches.
P.L. Zinzani, Bologna (Italy), et al.
Authors Conclusion from the abstract: In patients with R/R PMBL, nivolumab + BV demonstrated a high investigator‐assessed ORR of 73%, with 37% CR. TRAEs were consistent with the safety profiles of nivolumab and BV treatment alone. The combination of nivolumab + BV may be synergistic and is active in patients with R/R PMBL.
A.J. Ferreri, Milan (Italy), et al.
Authors Conclusion from the abstract: NGR‐hTNF/RCHOP is active and safe in pts with rPCNSL. CD13, the target of TNF, was expressed in tumor tissue and, consistently, NGR‐hTNF enhanced vascular permeability specifically in tumor and perilesional areas. This innovative approach deserves to be addressed as first‐line treatment in PCNSL pts.
D. Jagadeesh, Cleveland, OH (USA), et al.
Authors Conclusion from the abstract: These data represent the largest cohort of SOT‐related PTLD pts reported to date. Collectively, pts with lung and heart SOT‐related PTLD had significantly inferior OS and depth of response to 1st line therapy was a critical determinant for long‐term RFS and OS. Our data demonstrates improved outcomes in pts with newly diagnosed PTLD treated in the era of novel agents.